Felületes hólyagdaganatok intravesicalis BCG instillációjával elért eredményeink.

Translated title of the contribution: Results obtained by intravesical instillation of BCG in superficial bladder tumors

I. Romics, D. Bach, R. Christoph

Research output: Contribution to journalArticle

Abstract

The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26% and 15% as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.

Original languageHungarian
Pages (from-to)25-28
Number of pages4
JournalOrvosi Hetilap
Volume131
Issue number1
Publication statusPublished - Jan 7 1990

Fingerprint

Intravesical Administration
Mycobacterium bovis
Urinary Bladder Neoplasms
Immunotherapy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Felületes hólyagdaganatok intravesicalis BCG instillációjával elért eredményeink. / Romics, I.; Bach, D.; Christoph, R.

In: Orvosi Hetilap, Vol. 131, No. 1, 07.01.1990, p. 25-28.

Research output: Contribution to journalArticle

@article{906cad63d9ed4dcabb2070018b429966,
title = "Fel{\"u}letes h{\'o}lyagdaganatok intravesicalis BCG instill{\'a}ci{\'o}j{\'a}val el{\'e}rt eredm{\'e}nyeink.",
abstract = "The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26{\%} and 15{\%} as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.",
author = "I. Romics and D. Bach and R. Christoph",
year = "1990",
month = "1",
day = "7",
language = "Hungarian",
volume = "131",
pages = "25--28",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Felületes hólyagdaganatok intravesicalis BCG instillációjával elért eredményeink.

AU - Romics, I.

AU - Bach, D.

AU - Christoph, R.

PY - 1990/1/7

Y1 - 1990/1/7

N2 - The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26% and 15% as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.

AB - The authors carried out immunotherapy in bladder cancer patients in stage pTa-1 G1-2 NoMo. The strain Connaught BCG (120 mg) was instilled weekly for 6 consecutive weeks in 26 patients. Another 13 patients were treated with 150 mg BCG strain Pasteur. The patients were followed average 26 months in the first, 16 months in the second group. The recurring of the tumor were found in 26% and 15% as well. Side effects were experienced more often in the third group. The authors advice the BCG therapy of the superficial bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025702035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025702035&partnerID=8YFLogxK

M3 - Article

C2 - 2405331

AN - SCOPUS:0025702035

VL - 131

SP - 25

EP - 28

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 1

ER -